| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Autophagy and cell cycle regulators. N6-Isopentenyladenosine is a cytokinin that regulates plant growth and differentiation. In mammalian cells, it induces cell cycle arrest and apoptosis. It is an autophagy inhibitor.
|
|---|---|
| ln Vitro |
Through the disruption of autophagic flow, N6-isopentenyladenosine dual targeting of AMPK and Rab7 prenylation suppresses the growth of melanoma[2].
N6-Isopentenyladenosine induces cell cycle arrest and apoptosis in bladder carcinoma T24 cells. It has anti-melanoma activity. It acts as an autophagy inhibitor. Detailed IC50 values for specific cell lines are available from specialized databases. |
| ln Vivo |
In vivo activity data for N6-Isopentenyladenosine is not extensively detailed in standard references. As an anti-melanoma agent, it is expected to show efficacy in animal models of melanoma. Its role as an autophagy inhibitor suggests potential in cancer therapy.
|
| Enzyme Assay |
In vitro enzyme assays are not typically performed for this compound. Its mechanism of action involves modulation of autophagy and cell cycle arrest, which are assessed in cell-based assays. It is used as a tool to study cytokinin signaling and autophagy.
|
| Cell Assay |
Cells (e.g., bladder carcinoma T24 cells or melanoma cells) are treated with N6-Isopentenyladenosine. Cell viability is measured using MTT or CellTiter-Glo assays. Cell cycle analysis is performed by flow cytometry. Apoptosis is assessed by Annexin V/PI staining. Autophagy markers (e.g., LC3-II) are measured by Western blotting.
|
| Animal Protocol |
In vivo efficacy studies are performed in mouse xenograft models of melanoma or bladder carcinoma. N6-Isopentenyladenosine is administered intraperitoneally or orally. Tumor volume is measured by calipers. Tumors are harvested for histology and biomarker analysis (e.g., apoptosis and autophagy markers). Body weight and clinical signs are monitored.
|
| ADME/Pharmacokinetics |
N6-Isopentenyladenosine has a molecular weight of 335.36 and a molecular formula of C15H21N5O4. It is a base-modified ribonucleoside. It is soluble in DMSO. Detailed pharmacokinetic parameters such as oral bioavailability and half-life are available from specialized databases.
|
| Toxicity/Toxicokinetics |
Detailed toxicological profiles of N6-Isopentenyladenosine are not extensively reported. As a naturally occurring compound, it is expected to have a manageable safety profile. Cytotoxicity is assessed in parallel with anti-cancer activity to determine the selectivity index.
|
| References |
|
| Additional Infomation |
N(6)-(Δ(2)-isopentenyl)adenosine is a nucleoside analog in which the 6-amino nitrogen atom of adenosine is replaced by Δ(2)-isopentenyl. It has antitumor activity, plant growth regulation, and plant metabolism effects. It is a nucleoside analog belonging to N-ribosyl-N(6)-isopentenyl adenine. Its function is related to adenosine.
Isopentenyl adenosine (IPA) has been used in clinical trials for the treatment of nausea and surgical site infections. Ribosomal nucleosides have been reported in Arabidopsis thaliana and Rhodococcus, and there is relevant data. Ribosomal nucleosides are isopentenyl derivatives of adenosine, naturally occurring in some plants, and are purine nucleosides with potential antitumor activity. Ribopyridine may cause cell cycle arrest and apoptosis. N(6)-[Δ(3)-isopentenyl]adenosine. An isopentenyl derivative of adenosine, belonging to the cytokinin family of plant growth regulators. N6-Isopentenyladenosine is a research-grade compound. It is used as a tool to study autophagy, cell cycle regulation, and cancer biology. It is not approved for clinical use. Its molecular formula is C15H21N5O4 and its molecular weight is 335.36. |
| Molecular Formula |
C15H21N5O4
|
|---|---|
| Molecular Weight |
335.36
|
| Exact Mass |
335.159
|
| CAS # |
7724-76-7
|
| PubChem CID |
24405
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
647.2±65.0 °C at 760 mmHg
|
| Melting Point |
143-146°C
|
| Flash Point |
345.2±34.3 °C
|
| Vapour Pressure |
0.0±2.0 mmHg at 25°C
|
| Index of Refraction |
1.708
|
| LogP |
1.31
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
24
|
| Complexity |
461
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CC(=CCNC1=C2C(=NC=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)C
|
| InChi Key |
USVMJSALORZVDV-SDBHATRESA-N
|
| InChi Code |
InChI=1S/C15H21N5O4/c1-8(2)3-4-16-13-10-14(18-6-17-13)20(7-19-10)15-12(23)11(22)9(5-21)24-15/h3,6-7,9,11-12,15,21-23H,4-5H2,1-2H3,(H,16,17,18)/t9-,11-,12-,15-/m1/s1
|
| Chemical Name |
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-(3-methylbut-2-enylamino)purin-9-yl]oxolane-3,4-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (298.19 mM)
1M HCl : 100 mg/mL (298.19 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.45 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.45 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.45 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9819 mL | 14.9094 mL | 29.8187 mL | |
| 5 mM | 0.5964 mL | 2.9819 mL | 5.9637 mL | |
| 10 mM | 0.2982 mL | 1.4909 mL | 2.9819 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
